机构:[1]Integrative Research Laboratory of Breast Cancer, the Research Centre ofIntegrative Medicine, Discipline of Integrated Chinese and Western Medicine& The Second Affiliated Hospital of Guangzhou University of ChineseMedicine, Guangzhou 510006, Guangdong, China[2]Guangdong ProvincialKey Laboratory of Clinical Research on Traditional Chinese MedicineSyndrome, Guangdong Provincial Academy of Chinese Medical Sciences,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006,Guangdong, China广东省中医院大德路总院乳腺科门诊乳腺科大德路总院[3]College of Basic Medicine, Guangzhou University ofChinese Medicine, Guangzhou 510006, Guangdong, China[4]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, SpecialAdministrative Region, China
Background Recent findings suggested that premetastatic niche (PMN) is a prerequisite in mediating cancer metastasis. Previously we demonstrated that XIAOPI formula could inhibit breast cancer lung metastasis via inhibiting tumor associated macrophages (TAMs)-secreted CXCL1. Herein, we aimed to explore the effects of XIAOPI formula on preventing breast cancer PMN formation and its underlying molecular mechanisms. Methods CXCL1 expression of TAMs was detected by qPCR and Western blotting assay. The influences of XIAOPI formula on the proliferation of TAMs and 4 T1 in the co-culture system were tested by CCK8 or EdU staining. Transwell experiment was applied to determine the effects of XIAOPI formula on the invasion ability of HSPCs and 4 T1. Breast cancer xenografts were built by inoculating 4 T1 cells into the mammary pads of Balb/c mice and lung metastasis was monitored by luciferase imaging. Immune fluorescence assay was used to test the epithelial-mesenchymal transition process and PMN formation in the lung tissues. The effects of XIAOPI formula on TAMs phenotype, hematopoietic stem/progenitor cells (HSPCs) and myeloid-derived suppressor cells (MDSCs) were determined by flow cytometry. Results It was found that XIAOPI formula could inhibit the proliferation and polarization of M2 phenotype macrophages, and reduce CXCL1 expression in a dose-dependent manner. However, M1 phenotype macrophages were not significantly affected by XIAOPI formula. TAMs/CXCL1 signaling was subsequently found to stimulate the recruitment of c-Kit(+)/Sca-1(+) HSPCs and their differentiation into CD11b(+)/Gr-1(+) MDSCs, which were symbolic events accounting for PMN formation. Moreover, XIAOPI formula was effective in inhibiting HSPCs activation and suppressing the proliferation and metastasis of breast cancer cells 4 T1 induced by HSPCs and TAMs co-culture system, implying that XIAOPI was effective in preventing PMN formation in vitro. Breast cancer xenograft experiments further demonstrated that XIAOPI formula could inhibit breast cancer PMN formation and subsequent lung metastasis in vivo. The populations of HSPCs in the bone marrow and MDSCs in the lung tissues were all remarkably declined by XIAOPI formula treatment. However, the inhibitory effects of XIAOPI formula could be relieved by CXCL1 overexpression in the TAMs. Conclusions Taken together, our study provided preclinical evidence supporting the application of XIAOPI formula in preventing breast cancer PMN formation, and highlighted TAMs/CXCL1 as a potential therapeutic strategy for PMN targeting therapy.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81873306, 81973526, 81703749, 81703764]; Guangdong Science and Technology Department [2016A030306025]; Guangdong High-level Personnel of Special Support Program [A1-3002-16-111-003]; Department of Education of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2018KZDXM022, A1-2606-19-111-009]; Guangdong traditional Chinese medicine bureau project [20181132, 20182044]; PhD Start-up Fund of Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2017A030310213, 2018A030310506]; Science and Technology Planning Project of Guangdong Province [2017B030314166]; Guangzhou science and technology project [201904010407]; Specific Research Fund for TCM Science and Technology of Guangdong provincial Hospital of Chinese Medicine [YN2018MJ07, YN2018QJ08]
第一作者机构:[1]Integrative Research Laboratory of Breast Cancer, the Research Centre ofIntegrative Medicine, Discipline of Integrated Chinese and Western Medicine& The Second Affiliated Hospital of Guangzhou University of ChineseMedicine, Guangzhou 510006, Guangdong, China[2]Guangdong ProvincialKey Laboratory of Clinical Research on Traditional Chinese MedicineSyndrome, Guangdong Provincial Academy of Chinese Medical Sciences,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006,Guangdong, China
通讯作者:
通讯机构:[1]Integrative Research Laboratory of Breast Cancer, the Research Centre ofIntegrative Medicine, Discipline of Integrated Chinese and Western Medicine& The Second Affiliated Hospital of Guangzhou University of ChineseMedicine, Guangzhou 510006, Guangdong, China[2]Guangdong ProvincialKey Laboratory of Clinical Research on Traditional Chinese MedicineSyndrome, Guangdong Provincial Academy of Chinese Medical Sciences,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006,Guangdong, China[3]College of Basic Medicine, Guangzhou University ofChinese Medicine, Guangzhou 510006, Guangdong, China[4]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, SpecialAdministrative Region, China
推荐引用方式(GB/T 7714):
Yifeng Zheng,Neng Wang,Shengqi Wang,et al.XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling[J].CELL COMMUNICATION AND SIGNALING.2020,18(1):doi:10.1186/s12964-020-0520-6.
APA:
Yifeng Zheng,Neng Wang,Shengqi Wang,Bowen Yang,Honglin Situ...&Zhiyu Wang.(2020).XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling.CELL COMMUNICATION AND SIGNALING,18,(1)
MLA:
Yifeng Zheng,et al."XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling".CELL COMMUNICATION AND SIGNALING 18..1(2020)